Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.

Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. Abstract Text:

K R Irvine,J B Rao,S A Rosenberg,N P Restifo,

DNA immunization can result in the induction of Ag-specific cellular and humoral immune responses and in protective immunity in several Ag systems. To evaluate the utility of DNA-based immunization as a potential cancer treatment strategy, we employed an experimental murine tumor, CT26, expressing the model tumor-associated Ag, beta-galactosidase (beta-gal), designated CT26.CL25. A plasmid expressing beta-gal (pCMV/beta-gal) administered by particle-mediated gene delivery to the epidermis using a hand-held, helium-driven "gene gun" induced beta-gal-specific Ab and lytic responses. Immunization with this construct prevented the growth of pulmonary metastatic tumor, and the adoptive transfer of splenocytes generated by pCMV/beta-gal in vivo immunization and cultured in vitro with the beta-gal876-884 immunodominant peptide reduced the number of established pulmonary nodules. DNA immunization alone had little or no impact on the growth of established lung metastases. To enhance the function of DNA immunization for active immunotherapy, a panel of cytokines was added as adjuvants following DNA administration. Significant reduction in the number of established metastases was observed when human rIL-2, mouse rIL-6, human rIL-7, or mouse rIL-12 were given after DNA inoculation; mouse rIL-12 as an adjuvant had the most profound effect. These findings suggest that the cytokines involved in the activation and expansion of lymphocyte populations may improve the therapeutic effects of DNA immunization. Given the ease with which plasmid DNA can be prepared to high purity for safe use in humans with infectious diseases and cancers, DNA immunization administered together with cytokine adjuvant may be an attractive alternative to recombinant viral vaccines.

Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. Publishing Authors By Initials

KR Irvine,JB Rao,SA Rosenberg,NP Restifo,

For similar cells: cells, cultured: tumor cells, cultured research abstracts see: cells: cells, cultured: tumor cells, cultured research

PUBMED ID PMID:

MEDLINE DATE:

Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of immunology (Baltimore, Md. : 1950)

VOLUME: 156

Page Numbers: 238-45

Journal Abbreviation: J. Immunol.

ISSN: 0022-1767

DAY: 1

MONTH: Jan

YEAR: 1996

Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2985117

Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. Keywords Mesh Terms:

KEYWORDS: Tumor Cells, Cultured

MESH TERMS: therapy

Chemical & Substance for Abstract: Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. Information

Substance Name: DNA, Neoplasm

Registry Number: 0

Grant and Affiliation Information for Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.

AFFILIATION: Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Country: UNITED STATES

AGENCY: United States NCI

GRANT: Z01 BC010763-01

ACRONYM: BC

MEDLINETA: J Immunol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases Related Publications

• Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.
• Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways.
• Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".
• Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity.
• CD8+ T-cell memory in tumor immunology and immunotherapy.
• Cancer vaccines: progress reveals new complexities.
• Countering the 'counterattack' hypothesis.
• Creating therapeutic cancer vaccines: notes from the battlefield.
• Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.
• Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.
• DNA and RNA-based vaccines: principles, progress and prospects.
• Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy?
• Enhancement of tumor-specific immune response with plasmid DNA replicon vectors.
• Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function.
• Hierarchy, tolerance, and dominance in the antitumor T-cell response.
• IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.
• IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.
• Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice.
• Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice.
• Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.
• Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen.
• Natural selection of tumor variants in the generation of "tumor escape" phenotypes.
• NeuronMetrics: software for semi-automated processing of cultured neuron images.
• Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.
• Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.
• Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL.
• The future of interleukin-2: enhancing therapeutic anticancer vaccines.
• Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen.
• Toll-like receptors in tumor immunotherapy.
• Vaccines to die for.